A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea

Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2‐year efficacy and safety of nilotinib and their relationship...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Shin, Junghoon, Koh, Youngil, Yoon, Seo Hyun, Cho, Joo‐Youn, Kim, Dae‐Young, Lee, Kyoo‐Hyung, Kim, Hyeong‐Joon, Ahn, Jae‐Sook, Kim, Yeo‐Kyeoung, Park, Jinny, Sohn, Sang‐Kyun, Moon, Joon Ho, Lee, Yoo Jin, Yoon, Seonghae, Lee, Jeong‐Ok, Cheong, June‐Won, Kim, Kyoung Ha, Kim, Sung‐Hyun, Kim, Hoon‐Gu, Kim, Hawk, Nam, Seung‐Hyun, Do, Young Rok, Park, Sang‐Gon, Park, Seong Kyu, Bae, Sung Hwa, Song, Hun Ho, Shin, Dong‐Yeop, Oh, Doyeun, Kim, Min Kyoung, Jung, Chul Won, Park, Seonyang, Kim, Inho
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5943463/
https://ncbi.nlm.nih.gov/pubmed/29577674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1450
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados